Can we boost immune cells to fight cancer?
Immune therapies have cured cancer patients who do not respond to other conventional treatments including surgery, radiation, and chemotherapy. But there have also been severe adverse events — it’s hard to boost just the right immune cells.
What if we could increase the number of those particular immune cells that recognize the infection or cancer? It is possible to isolate the “antigen specific” immune cells that target the cancer from blood or tumor, and grow them in a petri dish. Only they don’t grow much and the cells are still exhausted.
What is Thyas doing?
2006, a Nobel Prize winning discovery by Dr. Yamanaka of Kyoto University showed any cell in your body — skin, nerve, immune, can be turned into a stem cell. Stem cells are a class of undifferentiated cells — like blank slates — that are able to differentiate into specialized cell types. In embryos these cells are used to build every part of the developing baby. Like an embryonic stem cell, your own stem cells can be grown into any other cell type in your body — skin, nerve, immune. The new cells made from your cells are still your cells. Your immune system will not reject them.
Another Kyoto scientist, Dr. Kaneko, applied Dr. Yamanaka’s iPSC technique to antigen specific immune cell production. Starting with exhausted immune cells that could ID the cancer or infectious pathogen, he converted killer T cells to stem cells, then back to killer T cells again. Lo and behold, the newly grown killer T cells remembered the specific target antigen of the cancer or infection. The newly grown killer T cells were young, fresh, ready for action. As many as needed to cure.
What is the Product?
The Nobel Prize winning technology is named “iPSC” — induced Pluripotent Stem Cells. The immune cells of interest are called “killer T cells” — the T stands for thymus, where the immume cells are trained not to attack self but to find their foreign antigen. iPSCs made from T cells are called “T-iPSC.” The new T cells are differentiated from T-iPSCs. Market potential is in the billions.
What needs to be done?
Governments impose high hurdles to approve medical treatments. We are testing all aspects of this therapy to confirm efficacy and safety. We are confident in eventually receiving approval for this cancer treatment technique. Just think…
- Your cells
- Strong and vigorous
- Specifically targeting the cancer or chronic infection
- As many as needed for a cure
Thyas is currently in the pre-clinical stage. Clinical trials will be conducted in Japan. We hope to file an Investigational New Drug (IND) by the end of 2019.
We need to optimize the procedure for the highest quality, fastest turnaround time, and lowest cost. To do this we need people, equipment, and lab space. For these we need funding.
How can I help?
We would be delighted to speak with you and give you more in depth information about the science and potential of T-iPSC.
To donate or invest, contact us at email@example.com
Please let others know about Thyas. Thank you!